C-Peptide

Abstract

Objective: C-peptide has been the most technically appropriate and theoretically reasonable substitute for β-cell activity. In equimolar concentration, insulin and C-peptide are co-secreted into the portal circulation. Methods: A total of 150 participants of diagnosed diabetes mellitus (DM) and 18–45 years aged were studied. Those diabetics were classified into three groups supported by fasting serum C-peptide (FC) level and low FC cluster comprised participants with FC level <0.6 ng/ml. Intermediate FC group comprised subject with FC level >0.6–1.8 ng/ml and high FC group comprised participants with FC >1.8 ng/ml. Results: The cutoff set of C-peptide was taken as 0.3–2.45 ng/ml. The prevalent diabetes among males was 85%–65% female. For the 150 diabetic participants, 18 (12%) were classified as type 1 DM (T1DM), 77 (51.3%) with type 2 DM, and the rest 55 (36.7%) as latent autoimmune diabetes in adults or MODY were perceived. In participants with T1DM, the mean serum C-peptide was slightly lower than in other diabetes forms. Considering the family history of diabetics in our research, detectable C-peptide in people with the family experience of diabetes was identified. Family diabetes history presence was seen in 15.5% of type 1 DM T1DM cases, while 84.5% of the remainder of the cases. Such classification is focused solely on family records and C-peptide rates which are subject to antibody screening, a genetic study for improved identification of the forms of diabetes. Conclusions: This result indicates that the diabetes measure C-peptide should be used in scientifically linked diabetes diagnosis, diabetes period, and subject age for appropriately managing persons with diabetes.